No quarterly revenue total was found in RETINALGENIX TECHNOLOGIES INC.'s SEC filings.
Retinalgenix Technologies Inc. (RTGN) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. As of Jun 30, 2026 it held $27,232 in cash and investments and $5,596 in total debt.
Revenue
—
Net income
$-307,397
+52.7% vs year-ago quarter
Operating cash flow
$-136,671
+1.7% vs year-ago quarter
Free cash flow
—
EPS
$-0.02
+33.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
18.84M
+1.3% vs year-ago quarter
Net cash
$21,636
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- RTGN (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Petaluma, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1836295
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Net income | -$307,397 | -$590,489 | -$623,127 | -$568,791 | -$649,418 |
| Diluted EPS | -$0.02 | -$0.03 | -$0.03 | -$0.03 | -$0.03 |
| Operating cash flow | -$136,671 | -$109,213 | -$128,219 | -$103,837 | -$139,072 |
| Total assets | $32,215 | $5,805 | $21,041 | $7,001 | $8,388 |
| Total liabilities | $2.7M | $2.6M | $2.3M | $2.2M | $2.0M |
| Stockholders' equity | -$2.6M | -$2.6M | -$2.3M | -$2.2M | -$2.0M |
| Cash and investments | $27,232 | $180 | $14,774 | $92 | $839 |
| Total debt | $5,596 | $6,070 | $6,544 | $6,002 | $7,184 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Auditor change
|
Jul 15, 2026 | Jul 13, 2026 |
| 10-Q | Quarterly report | May 20, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Apr 15, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Mar 26, 2026 | Mar 22, 2026 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
All 114 Retinalgenix Technologies Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.